This company listing is no longer active
Vifor Pharma Valuation
Is VIFN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VIFN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VIFN (CHF166.15) is trading above our estimate of fair value (CHF111.29)
Significantly Below Fair Value: VIFN is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VIFN?
Other financial metrics that can be useful for relative valuation.
What is VIFN's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CHF10.78b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6x |
Enterprise Value/EBITDA | 19.8x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does VIFN's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 279.2x | ||
COPN Cosmo Pharmaceuticals | 1025.1x | 30.4% | CHF1.1b |
NOVN Novartis | 21.9x | 10.0% | CHF182.6b |
ROG Roche Holding | 15.3x | 8.6% | CHF178.2b |
BANB Bachem Holding | 54.4x | 15.4% | CHF6.1b |
VIFN Vifor Pharma | 73.5x | n/a | CHF10.8b |
Price-To-Earnings vs Peers: VIFN is expensive based on its Price-To-Earnings Ratio (73.5x) compared to the peer average (28.6x).
Price to Earnings Ratio vs Industry
How does VIFN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: VIFN is expensive based on its Price-To-Earnings Ratio (73.5x) compared to the European Pharmaceuticals industry average (18.2x)
Price to Earnings Ratio vs Fair Ratio
What is VIFN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 73.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VIFN's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.